Pembroke Pines, Florida 33024

  • Diabetes


Evaluate safety of non-adjunctive CGM use in CGM naive participants.

Study summary:

The study comprises recruitment and consenting of pediatric and adult participants. At entry, the following information will be collected: demographics, labs, clinical and diabetes history information (history of mild/severe hypoglycemia or DKA events in the past 6 months and SMBG testing frequency). There are 3 clinic visits: Study Entry, Month 6 and Month 12 . Monthly phone contacts will be made to assess for any mild/severe hypoglycemic or DKA events and any details surrounding an event. Clinic visits at Months 6 and 12 will capture frequency of SMBG testing, A1C level and PRO information. CGM data will be obtained during the study to assess for CGM adherence.


Inclusion Criteria: - Naïve to real-time CGM - Type 1 or insulin-requiring Type 2 diabetes - ≥ 2 years old Exclusion Criteria: - Use of RT-CGM, within the past 12 months - Pregnancy - Concomitant disease or condition that may compromise patient safety including and not limited to severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long term medical condition that would interfere with study related tasks or visits, or ongoing treatment for a significant malignancy. - Known (or suspected) significant allergy to medical grade adhesives - Dialysis



Primary Contact:

Study Director
David Price, MD
Dexcom-Medical Affairs

Stayce Beck, PhD, MPH
Phone: 8582036454

Backup Contact:

Nelly Njeru
Phone: 8582036379

Location Contact:

Pembroke Pines, Florida 33024
United States

Marisela Rodriguez
Phone: 954-507-6627

Site Status: Recruiting

Data Source:

Date Processed: September 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.